Use of bisphosphonates in cancer patients (Q41346428)

29 September 2017

1 reference

title

Use of bisphosphonates in cancer patients (English)

1 reference

29 September 2017

Body JJ

1

1 reference

29 September 2017

Coleman RE

series ordinal

2

1 reference

29 September 2017

Piccart M

series ordinal

3

1 reference

29 September 2017

publication date

1 July 1996

1 reference

29 September 2017

published in

Cancer Treatment Reviews

1 reference

29 September 2017

volume

22

1 reference

29 September 2017

issue

4

1 reference

29 September 2017

page(s)

265-287

1 reference

Differential action of the bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (Cl2MDP) on rat macrophage-mediated bone resorption in vitro.

29 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Bisphosphonates act on rat bone resorption through the mediation of osteoblasts

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Effects of two novel bisphosphonates on bone cells in vitro

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Passive immunization with anti-parathyroid hormone-related protein monoclonal antibody markedly prolongs survival time of hypercalcemic nude mice bearing transplanted human PTHrP-producing tumors

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Effects of passive immunization against parathyroid hormone-related protein: PTHrP is the responsible factor in mediating hypercalcemia in the walker carcinosarcoma 256 rat model

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Circulating PTHrP concentrations in tumor-induced hypercalcemia: influence on the response to bisphosphonate and changes after therapy

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Localization of parathyroid hormone-related protein mRNA expression in breast cancer and metastatic lesions by in situ hybridization

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Effects of secretory products of breast cancer cells on osteoblast-like cells

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Osteolytic bone metastasis in breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Histomorphometric evidence for osteoclast-mediated bone resorption in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Stimulation of bone resorption results in a selective increase in the growth rate of spontaneously metastatic Walker 256 cancer cells in bone

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Medical management of hypercalcaemia

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Dose/response study of aminohydroxypropylidene bisphosphonate in tumor-associated hypercalcemia

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: a prospective randomized crossover trial

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Evaluation of a 24-hour infusion of etidronate disodium for the treatment of hypercalcemia of malignancy

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Aminohydroxypropylidene bisphosphonate (APD) treatment for tumor-associated hypercalcemia: a randomized comparison between a 3-day treatment and single 24-hour infusions

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Optimal frequency of administration of pamidronate in patients with hypercalcaemia of malignancy

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Medical treatment of tumor-induced hypercalcemia and tumor-induced osteolysis: challenges for future research

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

A double-blind, crossover trial of intravenous clodronate in metastatic bone pain

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

High-dose intravenous pamidronate for metastatic bone pain

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Treatment of bone metastases from breast cancer and myeloma with pamidronate.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Pamidronate in patients with painful bone metastases, who failed initial treatment with hormones and/or chemotherapy

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Effect of daily etidronate on the osteolysis of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Palliative pamidronate treatment in patients with bone metastases from breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Bone and cancer: pathophysiology and treatment of metastases

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Advanced breast cancer: use of resources and cost implications

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast to bone

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Patterns of relapse and survival following radical mastectomy.Analysis of 716 consecutive patients

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Ten-year results of the treatment of primary operable breast carcinoma: A summary of 304 patients evaluated by the TNM system

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Estrogen receptor status: an important variable in predicting response to endocrine therapy in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Parathyroid hormone related protein and skeletal morbidity in breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

New bisphosphonates in osteoporosis

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause.

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Management of myeloma with bisphosphonates

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Osteoclast inhibition by pamidronate in metastatic prostate cancer: a preliminary study

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

BM 21.0955, a potent new bisphosphonate to inhibit bone resorption

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound

1 reference

https://api.crossref.org/works/10.1016/S0305-7372(96)90020-1

7 January 2021

10.1016/S0305-7372(96)90020-1

Identifiers

DOI

1 reference

29 September 2017

1 reference